Clinical trials: Carcinomas
Prostate Carcinoma
[18F]-rhPSMA PET-CT Imaging Performance in Patients With Prostate Cancer
This clinical trial evaluates [18F]-rh PSMA positron emission tomography (PET)-computed tomography (CT) imaging performance in patients with prostate cancer.
- Trial name
- NCT06580015
- Testing
- Computed Tomography, Flotufolastat F-18 Gallium, Medical Device Usage and Evaluation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
This randomized phase II trial studies how well giving cabozantinib-s-malate or paclitaxel works in treating patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cavity cancer.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT01716715
- Testing
- Cabozantinib S-malate, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 173 sites in United States
- Volunteers
- 111 people
- Sponsor
- National Cancer Institute (NCI)
Small Cell Carcinoma
Paclitaxel and Nortriptyline Hydrochloride in Treating Patients With Relapsed Small Cell Carcinoma
This phase I trial studies the side effects and best dose of nortriptyline hydrochloride when given together with paclitaxel in treating patients with small cell carcinoma that has come back.
- Trial name
- NCT02881125
- Testing
- Nortriptyline Hydrochloride, Paclitaxel
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Washington
Non-Small Cell Lung Cancer
Abequolixron (RGX-104) and Durvalumab in Lung Cancer
Non-Small Cell Lung Cancer (NSCLC) is one of the deadliest types of cancer. In lung cancer patients with a tumor that can be removed by surgery, adjuvant chemotherapy increases survival.
- Trial name
- NCT05911308
- Testing
- Durvalumab, Carboplatin, Abequolixron
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non-small Cell Lung Cancer
Immune Boost In Non-Small Cell Lung Cancer
Insufficient migration and activation of tumour specific effector T cells seems to be the one important reason for inadequate host anti-tumour immune response. Ionizing radiation can induce a variety of immune responses.
- Trial name
- RadImmune (NCT02319408)
- Testing
- Preoperative radiation
- Where
- 2 sites in Germany
- Volunteers
- 36 people
- Sponsor
- University Hospital Heidelberg
Carcinoma, Non-Small-Cell Lung
Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI
Cancer radiation treatment plans that employ lung functional avoidance methods require 3D maps that differentiate regions of healthy lung function from regions of compromised tissue to deliver sufficient dose to the tumor while…
- Trial name
- NCT05302817
- Testing
- Hyperpolarized xenon MRI
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Xemed LLC
Melanoma, Non Small Cell Lung Cancer
Exploratory Interventional Study of Prognostic Serum Biomarkers of Cancer Progression
Exploratory interventional study of prognostic serum biomarkers of cancer progression. Study of the relationship between the blood levels of soluble PDL1 and β2-microglobulin, and the clinical course of a metastatic solid tumor…
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Renal Cancer
- Trial name
- Onco-PDL1s/B2M (NCT05426317)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Clermont-Ferrand
Nasopharyngeal Carcinoma
BGT007 Cell Treatment of Nasopharyngeal Carcinoma
This is an exploratory study to evaluate the safety and preliminary effectiveness of BGT007 cells in the treatment of recurrent/metastatic nasopharyngeal carcinoma
- Trial name
- NCT05616468
- Testing
- BGT007 Cell Injection, Fludarabine, cyclophosphamide
- Where
- China
- Volunteers
- 23 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Advanced Solid Tumours, Non-small Cell Lung Cancer
Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers
Eligible subjects will be allocated to one of four cohorts based on tumour type and presence of specific biomarker. Subjects will receive open-label Dacomitinib as tablets for oral administration on a continuous daily basis at a…
- Conditions
- Advanced Solid Tumours, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04946968
- Testing
- Oral Dacomitinib
- Where
- 2 sites in Singapore
- Volunteers
- 24 people
- Sponsor
- National Cancer Centre, Singapore
Bladder Carcinoma, Breast Cancer
T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies
Background: Autologous T cells engineered to express a T cell receptor (TCR) targeting NY-ESO-1 will be infused back to patients with NY-ESO-1- expressing malignancies.
- Conditions
- Bladder Carcinoma, Breast Cancer, Esophagus Carcinoma, Lung Cancer
- Trial name
- NCT02457650
- Testing
- Cyclophosphamide, Fludarabine, Anti-NY ESO-1 TCR-transduced T cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shenzhen Second People's Hospital
HPV-Related Carcinoma
Integrating Primary & Secondary Interventions for Cervical Cancer Prevention in Primary Care Settings
The purpose of this study is to determine whether a mobile health educational intervention for Human PapillomaVirus (HPV) Vaccination promotion and cervical cancer screening in Primary Care settings is a feasible behavioral…
- Trial name
- NCT03033550
- Testing
- brief negotiated mobile application
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Boston Medical Center
Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer
Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer
This phase II trial is studying how well ispinesib works in treating patients with metastatic or unresectable kidney cancer. Ispinesib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT00354250
- Testing
- ispinesib
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Medullary Thyroid Cancer
Expanded Access of Cabozantinib in Medullary Thyroid Cancer
The objective of this study is to provide access to cabozantinib for eligible subjects with medullary thyroid cancer (MTC) pending approval of Exelixis' New Drug Application (NDA) by the FDA and commercial availability of…
- Trial name
- NCT01683110
- Testing
- cabozantinib
- Where
- 5 sites in United States
- Sponsor
- Exelixis
Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma
Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer
This phase II trial studies how well hypofractionated radiation therapy works in treating patients with stage 0-IIB breast cancer.
- Conditions
- Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage 0 Breast Cancer, Stage I Breast Cancer
- Trial name
- NOVEMBER (NCT03345420)
- Testing
- Hypofractionated Radiation Therapy
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- University of Utah
Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma
CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Phase II trial to study the effectiveness of CT-2103 in treating patients who have recurrent or persistent ovarian epithelial cancer or primary peritoneal cancer.
- Trial name
- NCT00045682
- Testing
- Paclitaxel Poliglumex
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Gynecologic Oncology Group
Nasopharyngeal Carcinoma
Effect of Oral Supplements on the Nutritional Status of Locally Advanced Nasopharyngeal Carcinoma Patients
Malnutrition is very common in locally advanced nasopharyngeal carcinoma(NPC) patients undergoing current chemoradiotherapy (CRT) due to dysphagia, mucositis, nausea and other treatment-related problems.
- Trial name
- NCT02776124
- Testing
- Healing Elements,Methuselah Medical Technology
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Non Squamous Lung Cancer
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
This study will evaluate the anti-cancer effects of crizotinib when compared with standard chemotherapy in patients with ALK positive lung cancer.
- Trial name
- PROFILE 1014 (NCT01154140)
- Testing
- treatment
- Where
- 249 sites in United States, Australia and 29 more
- Volunteers
- 343 people
- Sponsor
- Pfizer
NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC)
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine…
- Conditions
- NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus
- Trial name
- NCT07277413
- Testing
- IDE892, IDE397
- Where
- 23 sites in United States
- Volunteers
- 260 people
- Sponsor
- IDEAYA Biosciences
Breast Cancer Invasive
Long-term Follow-up of the TAM-01 Study and Pooled Analysis of Low-dose Tamoxifen Studies in Non-invasive or Microinvasive Breast Neoplasms
Low-dose tamoxifen (5 mg/day for three years, BabyTam) has emerged as a safer and effective alternative to the standard regimen (20 mg/day), reducing breast cancer recurrence with fewer adverse events.
- Trial name
- Babytam long (NCT06982313)
- Testing
- Tamoxifen (Nolvadex)
- Where
- 2 sites in Italy
- Volunteers
- 1,545 people
- Sponsor
- Ente Ospedaliero Ospedali Galliera
Carcinoma, Nonsquamous Non-small-cell Lung
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, versus (vs) pembrolizumab plus maintenance pemetrexed for the treatment of non-squamous NSCLC. The study's 2 primary hypotheses are: 1.
- Trial name
- NCT03976323
- Testing
- Pembrolizumab, Pemetrexed, Carboplatin
- Where
- 178 sites in United States, Argentina and 18 more
- Volunteers
- 1,003 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.